The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,760 | 546 | 1,187 | 1,744 |
| Net losses on financial instruments | -78 | -57 | -1 | -131 |
| Gain on sale of business | - | 0 | 0 | 0 |
| Equity in net earnings of other invested assets | 305 | 147 | 113 | 12 |
| Depreciation and amortization | 354 | 406 | 387 | 380 |
| Deferred income taxes | -274 | -322 | 269 | -52 |
| Impairment of property and equipment | 4 | 38 | 70 | - |
| Share-based compensation | 55 | 30 | 84 | 81 |
| Receivables, net | 1,174 | -756 | -815 | 923 |
| Other invested assets | 0 | -70 | 35 | 30 |
| Other assets | 1,552 | -460 | -201 | -43 |
| Policy liabilities | 1,590 | 1,101 | -1,260 | -213 |
| Unearned income | 266 | -338 | 270 | -79 |
| Accounts payable and other liabilities | 2,886 | -2,259 | -151 | 738 |
| Income taxes | 644 | -284 | -616 | 246 |
| Other, net | - | 30 | -26 | - |
| Net cash provided by operating activities | 4,332 | 84 | 1,135 | 2,054 |
| Purchases of investments | 4,735 | 2,761 | 4,163 | 4,138 |
| Proceeds from sale of investments | 3,094 | 2,666 | 2,975 | 3,533 |
| Maturities, calls and redemptions from investments | 552 | 576 | 447 | 324 |
| Changes in securities lending collateral | 313 | -191 | 110 | 176 |
| Purchases of subsidiaries, net of cash acquired | -5 | -33 | -1 | -50 |
| Proceeds from sales of subsidiaries, net of cash sold | - | 0 | 0 | 0 |
| Purchases of property and equipment | 235 | 293 | 360 | 267 |
| Other, net | 10 | -52 | 14 | 13 |
| Net cash provided by (used in) investing activities | -1,642 | 464 | -1,224 | -687 |
| Proceeds from long-term borrowings, net issuance costs | - | -3 | 2,994 | 0 |
| Repayments of long-term borrowings | 750 | -3 | 900 | 0 |
| Proceeds from short-term borrowings | 724 | 515 | 990 | - |
| Repayments of short-term borrowings | 150 | 545 | 1,170 | -110 |
| Changes in securities lending payable | 313 | -190 | 110 | 176 |
| Changes in bank overdrafts | -1,152 | 1,235 | -554 | 85 |
| Repurchase and retirement of common stock | 1,124 | 471 | 876 | 378 |
| Cash dividends | 376 | 377 | 381 | 385 |
| Proceeds from issuance of common stock under employee stock plans | 37 | 58 | 0 | -2 |
| Taxes paid through withholding of common stock under employee stock plans | 34 | 1 | -9 | -83 |
| Other, net | -3 | 12 | 21 | 3 |
| Net cash used in financing activities | -2,515 | 236 | 243 | -308 |
| Effect of foreign exchange rates on cash and cash equivalents | -9 | -6 | -1 | 1 |
| Change in cash and cash equivalents | 166 | 778 | 153 | 1,060 |
| Cash and cash equivalents at beginning of period | 9,491 | 8,713 | 8,560 | 7,500 |
| Cash and cash equivalents at end of period | 9,657 | 9,491 | 8,713 | 8,560 |
Elevance Health, Inc. (ELV)
Elevance Health, Inc. (ELV)